Featured Post:
Patients with the same cancer diagnosis are often recommended the same treatment regimens. Unfortunately, some therapies work better in some patients than in others, and the treatment journey can be different for each patient.
Subscribe to receive our latest blog posts covering a wide range of topics, from groundbreaking discoveries to cutting-edge advancements and industry trends.
Cancerworld | Feb 23, 2023
The Independent | Feb 8, 2023
Oxford BioDynamics Plc (AIM: OBD) is a global biotech company advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. Its flagship product, EpiSwitch CiRT, predicts how a patient will respond to immune checkpoint inhibitor therapies. OBD's proprietary EpiSwitch® platform harnesses 3D genomic regulation biomarkers to develop molecular diagnostic classifiers for numerous indications, including predicting response to therapy, patient prognosis, disease diagnosis, and residual disease monitoring. For more information, please visit myOBDX.com.
Learn About OBD
